本文選題：藥品價(jià)格　切入點(diǎn)：德國(guó)　出處：《中國(guó)藥房》2017年25期

【摘要】：目的:為完善我國(guó)藥品價(jià)格規(guī)制政策提供參考。方法:運(yùn)用文獻(xiàn)研究、制度比較等方法,歸納總結(jié)德國(guó)、日本和我國(guó)臺(tái)灣地區(qū)藥品價(jià)格規(guī)制政策的共性和特色,借鑒其成功經(jīng)驗(yàn)。結(jié)果與結(jié)論:德國(guó)、日本和我國(guó)臺(tái)灣地區(qū)藥品價(jià)格管理各有特色。德國(guó)實(shí)行參考價(jià)格制度和新藥定價(jià)機(jī)制,是最早實(shí)行參考價(jià)格制度的國(guó)家;日本采用新藥創(chuàng)新性加價(jià)、仿制藥遞減定價(jià)和藥品價(jià)格再調(diào)整體制;我國(guó)臺(tái)灣地區(qū)實(shí)行分類(lèi)分組差別定價(jià)、鼓勵(lì)競(jìng)爭(zhēng)議價(jià)并定期對(duì)藥價(jià)調(diào)查與調(diào)價(jià)。德國(guó)、日本和我國(guó)臺(tái)灣地區(qū)均將醫(yī)保支付價(jià)作為藥價(jià)管理的核心,采取綜合手段規(guī)制藥品價(jià)格,同時(shí)也都注重對(duì)市場(chǎng)價(jià)格的監(jiān)測(cè)和定期調(diào)整,價(jià)格談判和藥物經(jīng)濟(jì)學(xué)等多種定價(jià)方法被廣泛應(yīng)用。以價(jià)值為基礎(chǔ)的定價(jià)是目前藥品價(jià)格政策改革的趨勢(shì),我國(guó)在完善藥品價(jià)格管理制度時(shí)可有所借鑒。
[Abstract]:Objective: to provide a reference for perfecting the policy of drug price regulation in China. Methods: by means of literature research and institutional comparison, the common features and characteristics of drug price regulation policies in Germany, Japan and Taiwan were summarized. Results and conclusions: drug price management in Germany, Japan and Taiwan has its own characteristics. Germany implements reference price system and new drug pricing mechanism, which is the first country to implement reference price system. Japan uses innovative new drug price increase, generic drug decline pricing and drug price readjustment system; Taiwan region of China implements classified grouping and differential pricing, encourages competition and bargaining, and regularly investigates and adjusts drug prices. Both Japan and Taiwan take the medical insurance payment price as the core of drug price management and adopt comprehensive measures to regulate drug prices. At the same time, they also attach importance to the monitoring and regular adjustment of market prices. Many pricing methods, such as price negotiation and pharmacoeconomics, are widely used. Value-based pricing is the trend of drug price policy reform at present, which can be used for reference in perfecting the drug price management system in China.
【作者單位】： 北京大學(xué)藥學(xué)院藥事管理與臨床藥學(xué)系;北京大學(xué)醫(yī)藥管理國(guó)際研究中心;
【基金】：國(guó)家自然科學(xué)基金青年項(xiàng)目(No.71503017)
【分類(lèi)號(hào)】：R95
，

本文編號(hào)：1671175